Modern Hybrid Imaging in Patients With OSCC (PETOSCC)
2020年2月19日 更新者:Wuerzburg University Hospital
Modern Hybrid Imaging for Staging and Monitoring Patients With Oral Squamous Cell Carcinoma
Prospective diagnostic study to determine the diagnostic accuracy of preoperative 18F--fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in detecting local tumor extent, cervical lymph node metastases and distant metastases/secondary primary tumor.
研究概览
地位
完全的
条件
研究类型
观察性的
注册 (实际的)
265
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
Würzburg、德国、97070
- Department of Cranio- and Maxillofacial Surgery
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
取样方法
概率样本
研究人群
Patient with squamous cell carcinoma of the oral cavity,
描述
Inclusion Criteria:
- Histopathological proven head and neck carcinoma
- Written inform consent
- 18 years of age
Exclusion Criteria:
- Cancer of unknown primary
- En-bloc resection of lymph node levels
- Uncertainties regarding the removed lymph node levels
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Diagnostic accuracy of FGD-PET/CT to detect the primary tumor
大体时间:2013-2018
|
Visual assessment of FDG-PET/CT will be performed according to current guidelines.
The localization, expansion, and infiltration of osseous structures will be recorded.
The outcome measure is the correct diagnosis (1 = correct; 0 = false) with regards to the histopathological analysis.
The outcome measure will then be used to calculate the diagnostic accuracy of FDG-PET/CT to detect the primary tumor.
|
2013-2018
|
|
Diagnostic accuracy of FGD-PET/CT to detect lymph nodes metastases
大体时间:2013-2018
|
Visual assessment of FDG-PET/CT will be performed according to current guidelines.
The presence and number of nodal metastasis will be recorded for each cervical lymph node level.
The outcome measure is the correct diagnosis (1 = correct; 0 = false) with regards to the histopathological analysis.
The analysis will be performed on a patient level (lymph node metastasis yes/no), on the nodal metastatic involvement of cervical sides and lymph node levels.
The outcome measure will then be used to calculate the diagnostic accuracy of FDG-PET/CT to detect lymph node metastases.
|
2013-2018
|
|
Diagnostic accuracy of FGD-PET/CT to detect distant lymph node metastases.
大体时间:2013-2018
|
Visual assessment of FDG-PET/CT will be performed according to current guidelines.
The presence, localization and number of distant nodal metastasis will be recorded.
The outcome measure is the correct diagnosis (1 = correct; 0 = false) with regards to the histopathological analysis.
The outcome measure will then be used to calculate the diagnostic accuracy of FDG-PET/CT to detect lymph node metastases.
|
2013-2018
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Diagnostic accuracy of MRI to detect the primary tumor
大体时间:2013-2018
|
Visual assessment of MRI will be performed according to current guidelines.
The localization, expansion, and infiltration of osseous structures will be recorded.
The outcome measure is the correct diagnosis (1 = correct; 0 = false) with regards to the histopathological analysis.
The outcome measure will then be used to calculate the diagnostic accuracy of MRI to detect the primary tumor.
|
2013-2018
|
|
Diagnostic accuracy of MRI to detect lymph nodes metastases
大体时间:2013-2018
|
Visual assessment of MRI will be performed according to current guidelines.
The presence and number of nodal metastasis will be recorded for each cervical lymph node level.
The outcome measure is the correct diagnosis (1 = correct; 0 = false) with regards to the histopathological analysis.
The analysis will be performed on a patient level (lymph node metastasis yes/no), on the nodal metastatic involvement of cervical sides and lymph node levels.
The outcome measure will then be used to calculate the diagnostic accuracy of MRI to detect lymph node metastases.
|
2013-2018
|
|
Diagnostic accuracy of CT to detect the primary tumor
大体时间:2013-2018
|
Visual assessment of CT will be performed according to current guidelines.
The localization, expansion, and infiltration of osseous structures will be recorded.
The outcome measure is the correct diagnosis (1 = correct; 0 = false) with regards to the histopathological analysis.
The outcome measure will then be used to calculate the diagnostic accuracy of CT to detect the primary tumor.
|
2013-2018
|
|
Diagnostic accuracy of CT to detect lymph nodes metastases
大体时间:2013-2018
|
Visual assessment of CT will be performed according to current guidelines.
The presence and number of nodal metastasis will be recorded for each cervical lymph node level.
The outcome measure is the correct diagnosis (1 = correct; 0 = false) with regards to the histopathological analysis.
The analysis will be performed on a patient level (lymph node metastasis yes/no), on the nodal metastatic involvement of cervical sides and lymph node levels.
The outcome measure will then be used to calculate the diagnostic accuracy of CT to detect lymph node metastases.
|
2013-2018
|
|
Diagnostic accuracy of CT to detect distant lymph node metastases.
大体时间:2013-2018
|
Visual assessment of CT will be performed according to current guidelines.
The presence, localization and number of distant nodal metastasis will be recorded.
The outcome measure is the correct diagnosis (1 = correct; 0 = false) with regards to the histopathological analysis.
The outcome measure will then be used to calculate the diagnostic accuracy of CT to detect lymph node metastases.
|
2013-2018
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Urs Müller-Richter, MD, DDS, PhD、Dpt. of CMF, University Hospital Wuerzburg
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2013年6月28日
初级完成 (实际的)
2018年12月31日
研究完成 (实际的)
2018年12月31日
研究注册日期
首次提交
2020年2月4日
首先提交符合 QC 标准的
2020年2月19日
首次发布 (实际的)
2020年2月21日
研究记录更新
最后更新发布 (实际的)
2020年2月21日
上次提交的符合 QC 标准的更新
2020年2月19日
最后验证
2020年2月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.